BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22236866)

  • 1. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
    Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
    Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
    Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
    Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
    Hirsh V
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
    Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
    J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
    Kentepozidis N; Kotsakis A; Soultati A; Agelaki S; Christophylakis Ch; Agelidou M; Chelis L; Papakotoulas P; Vamvakas L; Zafiriou Z; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):605-12. PubMed ID: 23338050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.
    Spigel DR; Anthony Greco F; Waterhouse DM; Shipley DL; Zubkus JD; Bury MJ; Webb CD; Hart LL; Gian VG; Infante JR; Burris HA; Hainsworth JD
    Lung Cancer; 2012 Oct; 78(1):70-5. PubMed ID: 22947511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.
    Tsai CM; Au JS; Chang GC; Cheng AC; Zhou C; Wu YL
    J Thorac Oncol; 2011 Jun; 6(6):1092-7. PubMed ID: 21512405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
    Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
    J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.
    Bearz A; Passalacqua R; Alabiso O; Cinieri S; Gridelli C; Cravesana C; Crinò L
    Clin Drug Investig; 2012 Nov; 32(11):755-60. PubMed ID: 23018280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of 31 cases treated with bevacizumab-based chemotherapy].
    Yamashita N; Takahashi K; Ohata K; Okita K; Ito S; Yoshimura T; Hanawa T; Fujita N
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):221-5. PubMed ID: 22333631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].
    Zarza V; Couraud S; Bosc C; Toffart AC; Moro-Sibilot D; Souquet PJ
    Rev Mal Respir; 2014 Sep; 31(7):601-7. PubMed ID: 25239581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.
    Leon L; Vázquez S; Gracia JM; Casal J; Lazaro M; Firvida JL; Amenedo M; Santome L; Macia S
    Expert Opin Pharmacother; 2012 Jul; 13(10):1389-96. PubMed ID: 22630129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
    Somer RA; Sherman E; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of chemotherapy for patients with advanced non-small cell lung cancer.
    Pennell NA
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS46-50. PubMed ID: 22614966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.